Oncology

T cells
#Adagene #Collaboration #Colorectal cancer #Oncology #T cell engagers #Third Arc Bio

Adagene and Third Arc Bio collaborate on masked CD3 T cell engagers

Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens.   In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide.   Adagene will receive an upfront payment of $5… Read More

#Business & Investment #News

Johnson & Johnson head office
#Johnson & Johnson #Mergers and acquisitions #Oncology #Prostate cancer

Oncology company Halda acquired by Johnson & Johnson

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion, payable in cash at closing, subject to customary adjustments.  Halda’s portfolio includes HLD-0915, a first-in-class, oral Regulated Induced Proximity Targeting Chimeras (RIPTAC) therapeutic, in development for metastatic castration-resistant prostate cancer (mCRPC).  HLD-0915 is an innovative bifunctional small molecule therapy designed… Read More

#Business & Investment #News

Nasal spray
#Cancer treatment #Cervical cancer #HPV #Immunology / Virology & Vaccines #Oncology

Scientists create nasal vaccine for treating cervical cancer

Researchers at Chiba University in Japan have developed a new nasal therapeutic vaccine as a non-invasive treatment option for cervical cancer.   Cervical cancer is primarily caused by the human papillomavirus (HPV), but there are no approved therapeutic medicines to treat existing infections or HPV-associated cancers. … Read More

#Cancer Research #Editor's Choice #News

#Acute Myeloid Leukaemia #Cancer research #Leukaemia #Oncology #Syndax Pharmaceuticals

Leading the charge in cancer care

DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of Syndax, about its work on developing therapeutics for challenging cancer targets.    RA: What are the unmet needs in relapsed or refractory acute leukaemia. How great is this unmet need in paediatric patients?   MM: Syndax is initially focused on two… Read More

#Exclusive Content

#Cancer treatment #Intensity Therapeutics #Oncology #Phase II trial #Solid tumours

Intratumoral injection drives local and systemic anti-cancer activity

eBioMedicine, a Lancet Discovery Science journal, has published Intensity Therapeutics’ Phase I/II IT-01 clinical study manuscript for the treatment of metastatic or refractory cancers.   According to the data, in heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Leukaemia #Oncology #Proteomics

Discovery of ‘handbrake’ enzyme offers cancer breakthrough 

Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance.  The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular… Read More

#Cancer Research #News

Cancer cells
#Antibody drug conjugate (ADC) #Circulating tumour cell enumeration #Oncology

Results show CTCs could be ‘dynamic biomarkers in oncology’

CellBxHealth, the company specialising in circulating tumour cell (CTC) solutions, has presented encouraging results on cell visualisation and biomarker analysis, which could shape antibody-drug conjugate (ADC) therapy.  The results, presented at the World ADC conference in San Diego, US, demonstrate successful cell visualisation and biomarker analysis across ADC targets… Read More

#Cancer Research #News

Human data concept
#Data #Drug discovery #Oncology #Spatial biology #The Francis Crick Institute

How is spatial biology rewriting the rules of oncology drug discovery?

Diana Turner explores how Nature’s 2024 ‘Method of the Year’ is transforming our understanding of cancer.    Invented in the early 2000s, spatial biology is a technique revealing unique insights into biomolecules and how they interact within their cellular and tissue architecture. As a result, and as technologies advance in accuracy, there is increasing industry interest and adoption for uses of spatial biology in… Read More

#Exclusive Content

#3D imaging #3D modelling #Cell Science #Drug discovery #eBook #Live cell analysis #Oncology #Spheroid

eBook: Unlock the full potential of spheroid models in research

3D spheroid models and live-cell analysis are powerful tools transforming drug discovery and cancer science. Download this eBook ‘Exploring the Versatility of Using 3D Spheroid Models in Research‘ from Sartorius to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more… Read More

#News

#3D imaging #3D modelling #Cell Science #Drug discovery #eBook #Live cell analysis #Oncology #Spheroid

Go beyond 2D – Unlock the full potential of spheroid models in research

3D spheroid models and live-cell analysis – powerful tools transforming drug discovery and cancer science! Download the eBook to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more reliable, clinically relevant cancer models Download now and accelerate your breakthroughs.  … Read More

#eBooks #Resources

#Eisai #Liver cancer #Merck #Oncology #Phase III trial

Eisai and Merck’s LEAP-012 trial fails to meet primary endpoint

Eisai and Merck (MSD outside of the US and Canada) have announced that in a Phase III trial, Lenvima (lenvatinib) plus Keytruda (pembrolizumab) with transarterial chemoembolisation (TACE) did not achieve statistical significance for overall survival (OS) compared to TACE alone.   The LEAP-012 trial evaluated the combination in… Read More

#Cancer Research #News

#Artificial intelligence (AI) #Multiomics #Oncology

How AI and multiomics are accelerating drug discovery

DDW Editor Reece Armstrong speaks to Tyrone Lam, Chief Business Officer (CBO) at GATC Health, about how multiomics and AI can advance drug discovery in areas such as opioid use disorder (OUD).     RA: What are the current challenges of traditional drug development processes?   TL: Traditional drug development is often… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Cancer research #Oncology

Antibody-drug conjugates: A targeted approach in cancer therapy

Janet Sasso, Information Scientist at CAS, provides an overview of the antibody drug conjugate market and its potential in oncology.    Antibody-drug conjugates (ADCs) are a class of targeted biopharmaceuticals that combine the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, a combination attracting growing attention in the… Read More

#Exclusive Content

#Drug discovery #Oncology #Radiopharmaceuticals #Theranostics

The promise of therapeutic radiopharmaceuticals

Denis R Beckford-Vera, Head of Radiopharmacology at Champions Oncology explores how radiopharmaceuticals can benefit from the use of patient-derived xenograft models.  The rising promise of radiopharmaceuticals Targeted radionuclide therapies (TRTs) are rapidly becoming a major force in oncology drug development. These agents combine a tumour-targeting molecule with a radioactive isotope,… Read More

#Exclusive Content

Pancreatic cancer
#iOnctura #Oncology #Pancreatic cancer #Phase I trial

mPDAC treatment reaches primary endpoint in Phase Ib trial

Cambritaxestat, a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), has met its primary endpoint in a Phase Ib trial. Cambritaxestat, an oral autotaxin (ATX) inhibitor, was evaluated in patients with previously untreated mPDAC. The treatment demonstrated safety, tolerability and anti-tumour responses, with data presented at the European Society… Read More

#Cancer Research #News